Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.

about

Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.

Item

http://www.wikidata.org/entity/Q47304122

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacology and drug developm ...... e French medical pharmacology.

@en

Pharmacology and drug developm ...... e French medical pharmacology.

@nl

type

Item

label

Pharmacology and drug developm ...... e French medical pharmacology.

@en

Pharmacology and drug developm ...... e French medical pharmacology.

@nl

prefLabel

Pharmacology and drug developm ...... e French medical pharmacology.

@en

Pharmacology and drug developm ...... e French medical pharmacology.

@nl

P1476

Pharmacology and drug developm ...... he French medical pharmacology

@en

P2093

Olivier Blin

http://www.w3.org/2001/XMLSchema#string

P2860

An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

Heterogeneity of the Ehlers-Danlos syndrome: description of three clinical types and a hypothesis to explain the basic defect(s)

Drug repositioning: identifying and developing new uses for existing drugs

Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.

Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type.

Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.

Discovery and preclinical validation of drug indications using compendia of public gene expression data.

Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.

Methodology for small clinical trials.

The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome.

P304

685-694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/FCP.12314

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pierre Boutouyrie

Joëlle Micallef

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28779530

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

rare disease